Macquarie Group
TAK icon

Macquarie Group’s Takeda Pharmaceutical TAK Stock Holding History

Macquarie Group’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.19K Hold
324
– – ﹤0.01% 920
2026
Q1 		$6K Hold
324
– – ﹤0.01% 808
2025
Q4 		$5.05K Hold
324
– – ﹤0.01% 835
2025
Q3 		$4.74K Hold
324
– – ﹤0.01% 1578
2025
Q2 		$5.01K Hold
324
– – ﹤0.01% 1632
2025
Q1 		$4.82K Hold
324
– – ﹤0.01% 1680
2024
Q4 		$4.29K Hold
324
– – ﹤0.01% 1592
2024
Q3 		$4.61K Sell
324
-1,045,547
-100% -$14.8M ﹤0.01% 1639
2024
Q2 		$13.5M Sell
1,045,871
-1,200,878
-53% -$15.9M 0.02% 746
2024
Q1 		$31.2M Sell
2,246,749
-199,193
-8% -$2.9M 0.04% 574
2023
Q4 		$34.9M Sell
2,445,942
-1,313,556
-35% -$18.6M 0.04% 541
2023
Q3 		$58.2M Sell
3,759,498
-71,257
-2% -$1.1M 0.07% 357
2023
Q2 		$60.2M Sell
3,830,755
-77,980
-2% -$1.28M 0.07% 370
2023
Q1 		$64.4M Buy
3,908,735
+72,745
+2% +$1.16M 0.08% 334
2022
Q4 		$59.8M Sell
3,835,990
-158,054
-4% -$2.21M 0.07% 377
2022
Q3 		$51.8M Sell
3,994,044
-73,946
-2% -$1.03M 0.06% 410
2022
Q2 		$57.1M Sell
4,067,990
-153,391
-4% -$2.19M 0.06% 404
2022
Q1 		$60.5M Buy
4,221,381
+478,256
+13% +$7.02M 0.05% 458
2021
Q4 		$51M Sell
3,743,125
-953,998
-20% -$13.4M 0.04% 516
2021
Q3 		$76.9M Sell
4,697,123
-43,589
-0.9% -$732K 0.07% 386
2021
Q2 		$79.8M Buy
4,740,712
+439,437
+10% +$7.48M 0.07% 378
2021
Q1 		$78.5M Buy
4,301,275
+36,500
+0.9% +$657K 0.11% 225
2020
Q4 		$77.6M Buy
4,264,775
+290,037
+7% +$5.09M 0.11% 201
2020
Q3 		$70.9M Sell
3,974,738
-220,343
-5% -$4.01M 0.12% 182
2020
Q2 		$75.2M Sell
4,195,081
-844,716
-17% -$15.2M 0.13% 162
2020
Q1 		$76.5M Sell
5,039,797
-69,622
-1% -$1.26M 0.16% 122
2019
Q4 		$101M Sell
5,109,419
-191,217
-4% -$3.66M 0.14% 119
2019
Q3 		$91.2M Sell
5,300,636
-205,467
-4% -$3.55M 0.15% 118
2019
Q2 		$97.5M Buy
5,506,103
+724,835
+15% +$13.2M 0.16% 110
2019
Q1 		$97.4M Buy
+4,781,268
New +$96.2M 0.17% 106

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Macquarie Group's TAK Position: Q2 2026 in Review

Macquarie Group held its Takeda Pharmaceutical (TAK) position steady in Q2 2026 at 324 shares worth $5.19K. The position accounts for ﹤0.01% of the portfolio, ranked #920.

Macquarie Group first reported a position in TAK in Q1 2019 and has held it in 30 quarters since. The position peaked at $101M in Q4 2019. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Macquarie Group held 324 shares of Takeda Pharmaceutical worth $5.19K as of Q2 2026.
  • Macquarie Group left its Takeda Pharmaceutical share count unchanged in Q2 2026.
  • Takeda Pharmaceutical made up ﹤0.01% of Macquarie Group's portfolio in Q2 2026, its #920 holding.
  • Macquarie Group first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 30 quarters since.
  • Macquarie Group's Takeda Pharmaceutical position peaked at $101M in Q4 2019.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Macquarie Group's 13F filing for Q2 2026, filed 14 Aug 2026.